Douglas K Marks
@dougmarksmd
Followers
43
Following
1
Media
1
Statuses
28
Medical oncologist. Breast cancer specialist. New Yorker. Closet DIY enthusiast. Tweets my views alone.
New York, NY
Joined February 2017
Join us live on X tonight at 9:30 pm Central for our IDEO Xchange discussing the latest developments in #breastcancer with Drs. @Dr_RShatsky @hoperugo @AbiSivaMD @mabelonc @DrWGradishar @MeganKruseMD @gandhi_shipra @dougmarksmd @Neil_Iyengar @kristinrojasmd @NinaOncMD
0
5
6
A #breastcancer diagnosis doesn’t have to upend your whole life! A special thanks to @Perlmutter_CC’s Dr. Doug Marks (L) & @Kathie_JosephMD for joining @nyulangone’s @MarkPochapin (R) on #ChiefsRounds! Missed our conversation? https://t.co/4JyGqF4bZ1 to listen on your schedule!
0
4
11
Adding AKT Inhibitor Doubles PFS in Advanced, HR-Positive Breast Cancer
medpagetoday.com
In phase III trial, capivasertib benefited patients with or without AKT pathway alterations
0
0
1
TALENT Trial - hinting at the beginning of the end of cytotoxic chemotherapy. With targeted chemotherapy by ADC, replacing conventional cytotoxics. #sabcs2022
0
0
0
Trastuzumab Deruxtecan Is New Standard of Care for HER2-Low MBC https://t.co/2MchL4ocb4 via @onclive. While most oncs who prev rx TDxd are not surprised, still so impressed! Best said, these are modular drugs. Homerun here, and more to come #ADC #ASCO22
onclive.com
Treatment with fam-trastuzumab deruxtecan-nxki doubled progression-free survival and reduced the risk of death by 36% compared with physician's choice of chemotherapy for patients with HER2-low,...
0
0
1
Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy... https://t.co/vKjo6z1pYv Columbia colleagues, continue the multiplex in her2 . Similar findings across Non-luminal subtypes
0
0
1
Glad no longer in this phase of the pandemic! Grateful to my colleagues for working with me on this! This one is dedicated to our patients who bravely navigated their diagnoses amid the uncertainty of the early pandemic @Perlmutter_CC @perlmutterproud
https://t.co/1w9fhYIsd6
academic.oup.com
This article provides real-world data regarding the risk for SARS-CoV-2 infection and mortality in patients with breast cancer on active cancer treatment.
0
0
1
Our cancer experts just published in @OncJournal on the outcomes of breast cancer patients being treated during the #COVID19 pandemic. Read more about the findings from this study:
academic.oup.com
This article provides real-world data regarding the risk for SARS-CoV-2 infection and mortality in patients with breast cancer on active cancer treatment.
0
2
2
FDA Approves Adjuvant Olaparib for BRCA+, High-Risk Early Breast Cancer https://t.co/51ImyrOTda via @onclive. Targeted therapies for adjuvant management of high risk TNBC — IO and now germline pts with PARP. Great to see the needle moving.
onclive.com
The FDA has approved olaparib for the adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who have previously received chemotherapy either before...
0
0
1
Medical oncologist @AbreoNina leads a trial for HER2-positive #breastcancer to determine the safety and tolerability of pre-operative therapy with 12 weeks of taxane, trastuzumab (or FDA approved biosimilar) and pertuzumab. Learn more: https://t.co/raAzKmnAZA
0
2
5
Despite initial fairly negative Fda review — now approved. IO metrics will differ from conventional therapy, pCR inc/ EFS shines. Will be a theme
Merck & Co Inc (MRK.N) said on Tuesday that the U.S. Food and Drug Administration approved its immunotherapy Keytruda as a treatment for an early form of a tough-to-treat breast cancer in combination with chemotherapy.
0
0
0
Study Examines Relationship Between Risk of COVID-19 Infection and Breast Cancer Treatment - The ASCO Post
ascopost.com
In a study led by researchers at NYU Langone Health and its Perlmutter Cancer Center involving more than 3,000 women treated for breast cancer at the height of the COVID-19 pandemic in New York City,...
0
0
0
Chemotherapy does not increase COVID-19 risk vs. noncytotoxic therapies for breast cancer
healio.com
The COVID-19 pandemic has had a substantial impact on the delivery of cancer care. Concerns about increased risk for COVID-19 among immunocompromised patients have prompted some clinicians to adapt...
0
0
0
Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients Read for free! https://t.co/7qRlM9R6YJ
#Quantitativeimaging #Stroma #BreastCancer
0
2
4
https://t.co/3Cj6Y644W2 collateral damage - well said. Need to adjust to new normal quickly as to limited the lasting impact this will have
0
0
0
📢 #ASCO20 Virtual Scientific Program 👉 Friday, May 29-Sunday, May 31. Learn & collab across a variety of approaches, disciplines, and specialties w an engaging lineup of virtual scientific content https://t.co/OkTiL6tiDg
3
79
142
To keep on radar — like the term “not negatives”
jamanetwork.com
This quality improvement analysis of oral presentations of phase 3 randomized clinical trials evaluates the frequency and risks of emphasizing results of borderline significance.
0
0
0